Additionally, our PDX cohort harbors a range of genomic alterations in members of clinically actionable pathways previously reported to be affected in PCa [3,43], including the AR, PI3K, WNT, MAPK/ERK, DNA repair pathways and the cell cycle, which opens opportunities for preclinical PCa drug testing. Here, AR is linked to posterior cortical atrophy.